Inclusion Criteria:  Patients of both sexes, 25 to 65 years old, with chronic migraine according to IHS Classification System, 3rd edition Undergoing preventive treatment in a stable dose of the preventive medication for at least 2 months, who have not used cannabidiol to treat migraine. At least 5 days of migraine/migraine like attacks in the baseline period (4 weeks) As preventive drugs propranolol, topiramate, valproic acid/sodium valproate, flunarizine, amitriptyline, nortriptyline will be allowed. Patients whose preventive treatment for migraine is Botulinum Toxin Type A may participate in the study as long as the toxin application interval used is 4 months (duration of medication or placebo use) and who have already received treatment with toxin at least 2 times. If acute treatment is necessary, patients may use the medications as previously advised by the physician accompanying them, and may use common, combined painkillers, anti-inflammatory drugs, triptans, triptans combined with anti-inflammatory drugs, opioid analgesics.  Exclusion Criteria:  Patients with active liver disease pregnancy and/or women who intend to become pregnant or who do not make adequate use of contraceptive therapy/methods breastfeeding women use of cannabis during the study, whether with therapeutic or recreational intentions patients who are without preventive treatment or who have undergone a dose change in preventive migraine treatment less than two months before V1 . Patients whose exclusive treatment for chronic migraine is Botulinum Toxin Type A at intervals of less than 4 months. History of substance abuse or addiction, use of medical cannabis or products with CBD or THC in the last 30 days, history of allergy to CBD or related products elevated transaminases > 3x the normal value substance abusers patients using substances that are potent enzyme inducers, such as rifampicin, ketoconazole, theophylline, carbamazepine, phenytoin, phenobarbital and St. John's wort. - Patients using anticoagulants.